Tyler N. Starr

This study identifies Aminopeptidase N as the receptor for hedgehog merbecoviruses and shows restricted cross-species receptor use.

This study identifies two antibodies that recognize conserved SARS-CoV-2 RBD epitopes, revealing structural mechanisms for broad neutralization and escape pathways.

The paper analyzes mutations in SARS-CoV-2 RBDs using deep mutational scanning to identify changing amino acid preferences and epistatic interactions across variants.

Across 119 monoclonal germinal centers, B cell affinity rises reliably despite divergent phylogenies. Selection is noisy but persistent; mutability limits exploration. A DMS-based landscape shows saturating fitness and survivorship biases.

This paper introduces a model that separates mutation and selection processes in antibody language models to improve prediction of mutation effects on antibody function.

This study shows that re-infection with SARS-CoV-2 leads to broader and more potent antibodies against diverse sarbecovirus strains compared to antibodies from a prior infection.

This paper describes VYD222, a broadly neutralizing antibody effective against SARS-CoV-2 variants, including Omicron, and explains its structural basis for resistance to viral escape.

This paper designs multivalent RBD nanoparticle vaccines that overcome immune imprinting and provide broad protection against SARS-CoV-2 variants and sarbecoviruses.

HKU5 merbecoviruses use bat Pipistrellus abramus ACE2 and several artiodactyl ACE2s through a cryo-EM-defined binding mode distinct from other ACE2-using coronaviruses, showing independent evolution of ACE2 usage.

The paper isolates two human monoclonal antibodies that broadly neutralize PDCoV variants and identifies their mechanism of action.

This study identifies cross-reactive antibodies against SARS-CoV-2 and related sarbecoviruses that target conserved epitopes and show broad neutralization potential.

The paper measures mutational effects on SARS-CoV-2 BA.2.86 spike RBD and identifies epistatic shifts leading to the KP.3 variant's emergence.

The paper designs and characterizes trivalent miniprotein binders that neutralize SARS-CoV-2 variants with low pM IC50 values and provide prophylactic and therapeutic protection in mice.